Mepolizumab/omalizumabInfusion reaction following an off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1766卷 / 1期

关键词：

D O I：

10.1007/s40278-019-66264-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：192 / 192

相关论文

共 50 条

[21] OsimertinibFrailty and pneumonitis following off-label use: 2 case reports
Reactions Weekly, 2022, 1905 (1) : 406 - 406
[22] PembrolizumabHepatotoxicity and erythema following off-label use: 2 case reports
Reactions Weekly, 2022, 1900 (1) : 270 - 270
[23] AtropineVarious toxicities following off-label use: 2 case reports
Reactions Weekly, 2019, 1766 (1) : 66 - 66
[24] VenetoclaxNausea and cytopenia following off-label use: 2 case reports
Reactions Weekly, 2023, 1981 (1) : 354 - 354
[25] OblimersenThrombocytopenia following off-label use (compassionate use): 2 case reports
Reactions Weekly, 2020, 1795 (1) : 213 - 213
[26] Haloperidol/quetiapineQTc prolongation and dystonic reaction following off-label use: 2 case reports
Reactions Weekly, 2021, 1865 (1) : 204 - 204
[27] OfatumumabSeptic shock and anaphylactic reaction following off-label use of ofatumumab: 2 case reports
Reactions Weekly, 2019, 1744 (1) : 207 - 207
[28] Multiple drugsLack off efficacy following off-label use: 2 case reports
Reactions Weekly, 2022, 1910 (1) : 335 - 335
[29] ParacetamolHaemolysis following off-label use: 3 case reports
Reactions Weekly, 2022, 1917 (1) : 472 - 472
[30] SpironolactoneHyperkalaemia following off-label use: 3 case reports
Reactions Weekly, 2023, 1949 (1) : 385 - 385

← 1 2 3 4 5 →